[go: up one dir, main page]

WO2012038565A3 - PROTEINS OF THE CRY FAMILY AS MARKERS FOR DETERMINING THE RISK OF DEVELOPING AN α-SYNUCLEINOPATHY OR DETERMINING SAID DISEASE - Google Patents

PROTEINS OF THE CRY FAMILY AS MARKERS FOR DETERMINING THE RISK OF DEVELOPING AN α-SYNUCLEINOPATHY OR DETERMINING SAID DISEASE Download PDF

Info

Publication number
WO2012038565A3
WO2012038565A3 PCT/ES2011/000282 ES2011000282W WO2012038565A3 WO 2012038565 A3 WO2012038565 A3 WO 2012038565A3 ES 2011000282 W ES2011000282 W ES 2011000282W WO 2012038565 A3 WO2012038565 A3 WO 2012038565A3
Authority
WO
WIPO (PCT)
Prior art keywords
determining
disease
synucleinopathy
developing
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2011/000282
Other languages
Spanish (es)
French (fr)
Other versions
WO2012038565A2 (en
Inventor
Emilio FERNÁNDEZ ESPEJO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Sevilla
Original Assignee
Universidad de Sevilla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Sevilla filed Critical Universidad de Sevilla
Publication of WO2012038565A2 publication Critical patent/WO2012038565A2/en
Publication of WO2012038565A3 publication Critical patent/WO2012038565A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to a method for determining the risk of developing an α-synucleinopathy or determining said neurodegenerative disease, by means of the detection and/or quantification of Cry proteins, neurotoxic agents that can give rise to this disease. Preferably, the α-synucleinopathy is Parkinson's disease.
PCT/ES2011/000282 2010-09-21 2011-09-20 PROTEINS OF THE CRY FAMILY AS MARKERS FOR DETERMINING THE RISK OF DEVELOPING AN α-SYNUCLEINOPATHY OR DETERMINING SAID DISEASE Ceased WO2012038565A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201031403A ES2390990B2 (en) 2010-09-21 2010-09-21 PROTEINS OF THE CRY FAMILY AS MARKERS TO DETERMINE THE RISK TO DEVELOP AN ALPHA-SINUCLEINOPATIA OR DETERMINE SUCH DISEASE
ESP201031403 2010-09-21

Publications (2)

Publication Number Publication Date
WO2012038565A2 WO2012038565A2 (en) 2012-03-29
WO2012038565A3 true WO2012038565A3 (en) 2013-02-21

Family

ID=45874205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/000282 Ceased WO2012038565A2 (en) 2010-09-21 2011-09-20 PROTEINS OF THE CRY FAMILY AS MARKERS FOR DETERMINING THE RISK OF DEVELOPING AN α-SYNUCLEINOPATHY OR DETERMINING SAID DISEASE

Country Status (2)

Country Link
ES (1) ES2390990B2 (en)
WO (1) WO2012038565A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137692A1 (en) * 2007-05-03 2008-11-13 Link Medicine Corporation Treatment of synucleinopathies
WO2009152607A1 (en) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Methods and kits for diagnosing neurodegenerative disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137692A1 (en) * 2007-05-03 2008-11-13 Link Medicine Corporation Treatment of synucleinopathies
WO2009152607A1 (en) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Methods and kits for diagnosing neurodegenerative disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHADE A.R. ET AL.: "Nongenetic causes of Parkinson's disease", JOURNAL OF NEURAL TRANSMISSION [SUPPLEMENT], vol. 70, no. 3, 2006, pages 147 - 151 *
THIRUCHELVAM M. ET AL.: "Developmental exposure to the pesticides paraquat and maneb and the Parkinson'sdisease phenotype", NEURO TOXICOLOGY, vol. 23, no. 4-5, October 2002 (2002-10-01), pages 621 - 633 *

Also Published As

Publication number Publication date
ES2390990B2 (en) 2013-04-17
WO2012038565A2 (en) 2012-03-29
ES2390990A1 (en) 2012-11-20

Similar Documents

Publication Publication Date Title
EP2771649A4 (en) ELECTRONIC DIFFERENTIATION DEVICE FOR THE DETECTION OF BODY EXUDATION
WO2015061634A3 (en) Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
ZA201302022B (en) Nmr systems and methods for the detection of analytes
WO2011047146A3 (en) Methods of affinity maturing antibodies
EP2613151A4 (en) METHOD OF DETERMINING THE APPEARANCE OF CANCER OR THE RISK OF APPEARANCE OF CANCER
ZA201203717B (en) Assays for the detection of anti-tnf drugs autoantibodies
WO2014049427A3 (en) Self-leveling welding tractor with a sensor for determining the inclination or declination angle of the tractor
EP2825694A4 (en) AFFINITY REAGENTS FOR THE PURIFICATION OF PROTEINS
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
WO2014144721A3 (en) Treating th2-mediated diseases by inhibition of bromodomain-comprising proteins brd7 and brd9
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2012058220A3 (en) Anti-sod1 antibodies and uses thereof
WO2012085555A3 (en) Biomarkers for diagnosing schizophrenia
WO2012166971A3 (en) Method of assessing risk of pml
WO2014095510A3 (en) Method for determining a reference position as the starting position for an inertial navigation system
PL2545380T3 (en) Hmgb1 and anti-hmgb1 antibodies for the prognostic of neurological disorders
WO2011143574A3 (en) Plasma biomarkers for diagnosis of alzheimer's disease
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
HK1216546A1 (en) Method of assessing risk of pml
FR2972339B1 (en) METHOD FOR DETERMINING THE DIRECTION EYE
WO2017076919A3 (en) Methods for apolipoprotein detection
WO2013170057A3 (en) Quantification of lipoproteins
HK1246394A1 (en) 13+/17+ bin1 expression as a marker of cardiac disorders
WO2015077342A3 (en) Detection of arginine methylation of egfr for prediction of resistance to therapy
DK2313776T3 (en) IMMUNOASSAY FOR THE DETECTION OF NEUROTOXIC AMINO ACID CONNECTED WITH NEUROLOGICAL DISEASES

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11826440

Country of ref document: EP

Kind code of ref document: A2